Moderate

Chronic heart failure with reduced ejection fraction (HFrEF) — 4-pillar GDMT

Heart failure · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

LVEF <=40% with symptoms/signs of HF. Four guideline-directed drug classes (ARNI/ACEi, beta-blocker, MRA, SGLT2i) each independently cut mortality and HF hospitalisation. Start all four early at low dose and uptitrate, rather than maximising one before adding the next.

Red flags

  • Symptomatic hypotension, syncope or rising creatinine during uptitration
  • Hyperkalaemia >5.5 mmol/L (hold/reduce MRA and RAS inhibitor)
  • Worsening congestion / weight gain despite therapy
  • Recurrent admissions, need for inotropes — advanced HF
  • New broad QRS/LBBB with low EF (CRT candidate)
  • Sustained VT/VF or syncope (ICD/arrhythmia workup)

Assessment

Differential diagnosis

  • HFpEF (LVEF >=50%)
  • HF with mildly reduced EF (41-49%)
  • Valvular HF (severe AS/MR)
  • High-output failure (anaemia, thyrotoxicosis, AV fistula)
  • Constrictive pericarditis / restrictive cardiomyopathy
  • COPD / pulmonary cause of dyspnoea

Investigations

  • ECG (QRS width/LBBB for CRT eligibility, AF, prior MI)
  • NT-proBNP or BNP (diagnosis + prognosis)
  • Echocardiogram — LVEF, wall motion, valves, filling pressures
  • U&E, creatinine/eGFR, potassium (baseline + during titration)
  • FBC, ferritin/transferrin saturation (iron deficiency), TFTs, HbA1c
  • CXR (congestion, cardiomegaly)
  • Coronary assessment if ischaemic aetiology suspected (angiography/CT coronary)

Management

  • Confirm HFrEF on echo (LVEF <=40%) and treat reversible causes (ischaemia, arrhythmia, valve disease, thyroid, alcohol)
  • Start all four pillars early, low dose; do not wait to maximise one before adding the next
  • Check U&E/K+ and BP before and ~1-2 weeks after each uptitration; tolerate creatinine rise up to ~30-50% and K+ up to 5.5
  • Uptitrate each agent every 2-4 weeks to target or maximum tolerated dose
  • Add loop diuretic for congestion — lowest dose that keeps euvolaemia (does not improve mortality)
  • Treat iron deficiency (ferritin <100, or 100-299 with TSAT <20%) with IV iron
  • Assess for device therapy once on optimal GDMT: ICD if LVEF <=35% and >40 days post-MI / >3 months non-ischaemic; CRT if LVEF <=35% + LBBB + QRS >=150 ms in sinus rhythm
  • Refer to HF specialist/transplant-LVAD if advanced (persistent NYHA III-IV, recurrent admissions, inotrope dependence)

Drugs & doses

Sacubitril/valsartan (ARNI) 24/26 mg PO BD, uptitrate to target 97/103 mg BD — preferred over ACEi; needs 36 h washout after stopping ACEi
Ramipril 1.25-2.5 mg PO BD, target 5 mg BD (ACEi alternative if ARNI unsuitable)
Candesartan 4 mg PO once daily, target 32 mg (ARB if ACEi/ARNI not tolerated due to cough)
Bisoprolol 1.25 mg PO once daily, double every 2-4 wk to max 10 mg (HFrEF beta-blocker)
Carvedilol 3.125 mg PO BD, uptitrate to 25 mg BD (50 mg BD if >85 kg) [alternative beta-blocker]
Metoprolol succinate 12.5-25 mg PO once daily, target 200 mg [alternative beta-blocker]
Spironolactone 25 mg PO once daily, target 50 mg (MRA) — monitor K+ and renal function
Eplerenone 25 mg PO once daily, target 50 mg (MRA alternative, less gynaecomastia)
Dapagliflozin 10 mg PO once daily (SGLT2i; no titration needed, benefit independent of diabetes)
Empagliflozin 10 mg PO once daily (SGLT2i alternative)
Furosemide 20-40 mg PO once/twice daily, titrate to congestion (symptom relief only)
Ferric carboxymaltose IV per weight/Hb protocol for iron deficiency [verify local dose]
Dapagliflozin/empagliflozin and MRA: hold SGLT2i during acute illness/dehydration (euglycaemic DKA risk)

Disposition

Most managed as outpatient with HF nurse-led titration clinic; admit for decompensation, symptomatic hypotension, renal deterioration or arrhythmia. Early specialist HF referral for device assessment and advanced therapies.

Complications & pitfalls

  • Progressive pump failure / cardiogenic shock
  • Sudden cardiac death (ventricular arrhythmia)
  • Atrial fibrillation
  • Cardiorenal syndrome
  • Hyperkalaemia from RAS/MRA therapy
  • Cardiac cachexia, functional MR

Exam pearls

  • 2021 ESC and 2022 AHA/ACC/HFSA guidelines endorse early simultaneous 4-pillar therapy over sequential titration.
  • SGLT2i (dapagliflozin DAPA-HF, empagliflozin EMPEROR-Reduced) reduce HF outcomes even in non-diabetics and need no dose titration.
  • Ivabradine is add-on if sinus rhythm with HR >=70 despite max beta-blocker; vericiguat and hydralazine/nitrate (esp. in Black patients or where RAS blockade not tolerated) are further options.
  • ARNI contraindicated with ACEi (angioedema) and within 36 h of an ACEi dose.
  • Do not stop GDMT just because EF recovers — 'HF in remission' relapses on withdrawal (TRED-HF).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.